AIDS Research and Therapy最新文献

{"title":"Lenacapavir: a transformative advance in HIV therapy and prevention-promise, access, and equity in Africa.","authors":"Stephen Olaide Aremu, Deborah Bukola Aremu, Abdillahi Abdi Barkhadle","doi":"10.1186/s12981-026-00921-1","DOIUrl":"https://doi.org/10.1186/s12981-026-00921-1","url":null,"abstract":"<p><p>Lenacapavir is a first-in-class HIV capsid inhibitor with a long-acting formulation that enables twice-yearly dosing for both treatment and prevention. Its novel mechanism and extended dosing interval represent a paradigm shift in HIV care. Sub-Saharan Africa bears the highest global HIV burden but has historically experienced delayed access to biomedical innovations, raising concerns about equity and persistent global health disparities. This article presents a narrative review and policy analysis examining lenacapavir's scientific potential, its role in HIV treatment and prevention, and the structural, economic, and policy challenges affecting equitable access in African settings. Emerging evidence indicates that lenacapavir is highly effective in heavily treatment-experienced individuals, including those with multidrug-resistant HIV, and its long-acting pharmacokinetic profile supports sustained viral suppression. As a prevention strategy, twice-yearly administration offers a practical alternative to daily oral pre-exposure prophylaxis (PrEP), with the potential to improve adherence and overcome barriers related to stigma and pill burden. Despite its promise, equitable access across Africa may be limited by high costs, patent protections, restricted licensing agreements, health-system weaknesses, and evolving global HIV financing. These challenges could hinder timely introduction and widespread uptake, particularly in resource-constrained settings. Ensuring equitable access will require coordinated action among governments, international agencies, pharmaceutical manufacturers, donors, and civil society to strengthen affordability, availability, and implementation within existing HIV prevention and treatment programs. Lenacapavir represents a transformative advance in HIV therapy and prevention. Its impact in Africa will depend not only on scientific innovation but also on equity-focused policies, sustainable financing, and coordinated implementation strategies.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological adjustment, HIV knowledge, and antiretroviral treatment adherence in newly diagnosed HIV patients: a cross-sectional study from an Albanian infectious diseases clinic.","authors":"Sulejman Hafizi","doi":"10.1186/s12981-026-00920-2","DOIUrl":"10.1186/s12981-026-00920-2","url":null,"abstract":"<p><strong>Background: </strong>The first year after an HIV diagnosis is a period of intense psychological vulnerability, with elevated rates of depression, anxiety, and adjustment problems documented in multiple settings. However, data from Albania and Western Balkan contexts are scarce.</p><p><strong>Objective: </strong>To assess psychological adjustment, coping responses, HIV knowledge, and antiretroviral treatment (ART) adherence among adults diagnosed with HIV within the previous 12 months in Tirana, Albania.</p><p><strong>Methods: </strong>A cross-sectional study was conducted with 120 patients registered at the ambulatory HIV/AIDS clinic at the Infectious Diseases Hospital in Tirana.</p><p><strong>Inclusion criteria: </strong>patients diagnosed within the last 12 months. Measures included demographic data, an Albanian version of the Mental Adjustment to HIV Scale (MAHIVS), a researcher-developed, interviewer-administered structured HIV knowledge interview, and a short adherence assessment based on self-report and cross-checking against medical records/clinic records.</p><p><strong>Results: </strong>The mean age was 34 years (SD = 5); 26.7% were female, and 47 males identified as homosexual. HIV transmission knowledge was high (78% answered correctly), while awareness of biomedical issues (PrEP/PEP, viral load, information regarding fertility) was low. Participants reported high ART adherence, supported by medical records. MAHIVS scores indicated high helplessness (M = 21/36) coexisting with strong adaptive coping: Fighting Spirit/Self-Efficacy (M = 14/24), Personal Control (M = 11/16), and Positive Coping (M = 11/20).</p><p><strong>Conclusion: </strong>Newly diagnosed Albanian patients show a mixed adjustment profile; notable psychological distress combined with moderate to high adaptive responses. Early psychosocial and educational support focused on reducing helplessness and increasing HIV knowledge within routine HIV care may improve adjustment trajectories during the first-year post-diagnosis.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13628962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief communication: clinical jaundice is associated with poor adherence to boosted atazanavir among adults in an HIV clinic in Kampala, Uganda.","authors":"Angella Nabakooza, Sharon Kitibwakye Nakamanya, Eva Agnes Laker, Elizabeth Katana, Noela Owarwo, Isaac Lwanga, Barbara Castelnuovo, Mohammed Lamorde, Freddy Kitutu Eric","doi":"10.1186/s12981-026-00908-y","DOIUrl":"10.1186/s12981-026-00908-y","url":null,"abstract":"<p><strong>Background: </strong>Boosted atazanavir (ATV/r) is associated with clinical jaundice, which may affect ART adherence. However, the prevalence of clinical jaundice among people on ATV/r and its association with ART adherence is unknown in Uganda.</p><p><strong>Methods: </strong>We conducted a cross-sectional study among 236 adult patients on ATV/r at the Infectious Disease Institute. Clinical jaundice was assessed by self-report and observation; ART adherence was measured using the 8-item Morisky scale.</p><p><strong>Results: </strong>Period prevalence of clinical jaundice was 31.8%, while point prevalence was 21.1%. While 8.5% had poor adherence, clinical jaundice was a significant predictor of poor adherence (adjusted odds ratio = 3.03, 95% CI: 1.18-7.76, p = 0.021).</p><p><strong>Conclusion: </strong>Clinical jaundice is common among patients on ATV/r in Uganda and is associated with poor ART adherence. Strengthening pre-ATV/r (pre-switch) counselling and exploring safer regimen alternatives are required to improve outcomes.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13625245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond HIV: investigating key drivers of metabolic syndrome in midlife women with HIV in the INSTI era.","authors":"M Poliseno, G Brindicci, D Capruzzi, A Cianciaruso, N Colavito, V Giliberti, V Lobalsamo, G Metrangolo, E Milano, L Perrucci, C R Santoro, A Vigna, F Di Gennaro, A Saracino","doi":"10.1186/s12981-026-00913-1","DOIUrl":"10.1186/s12981-026-00913-1","url":null,"abstract":"<p><strong>Background: </strong>The contribution of lifestyle factors compared with HIV infection and antiretroviral therapy (ART)-related determinants to Metabolic Syndrome (MetS) in Women with HIV (WWH) remains uncertain.</p><p><strong>Objectives: </strong>To evaluate the prevalence and determinants of MetS in the era of Integrase Strand Transfer Inhibitors (INSTI).</p><p><strong>Design: </strong>Monocentric retrospective cohort study.</p><p><strong>Methods: </strong>We analyzed 297 WWH to assess the prevalence of MetS and its association with HIV-related and lifestyle factors.</p><p><strong>Results: </strong>MetS was diagnosed in 80 women (26%). Those with MetS showed lower CD4 nadir, longer HIV and ART duration, and greater exposure to protease inhibitors and INSTI, but none were independently associated with MetS or its components. Notably, lifestyle-related factors showed relatively strong associations with the study outcomes: physical activity was protective (OR 0.10, 95% CI 0.02-0.44), whereas physically demanding work increased risk (OR 6.58, 95% CI 2.03-26.26).</p><p><strong>Conclusions: </strong>Lifestyle-related factors appeared to show stronger associations with MetS risk compared to HIV-related variables, underscoring the importance of systematic lifestyle assessment and targeted interventions in women with HIV.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13625421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148366621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of HIV-1 low-level viremia on virologic and immunologic failure during antiretroviral therapy: a retrospective cohort study from 2005 to 2023 in Qinzhou City, Guangxi, China.","authors":"Long-Yu Liao, Ting Huang, Shi-Fu Deng, Chun-Xing Tao, Liang-Jia Wei, Hua-Yue Liang, Bo-Lin Wu, Li-Dan Zhang, Ying-Yuan Liang, Jin-Feng Qin, Hai-Song Wu, Qi-Jian Su, Bing-Yu Liang, Li-Jing Huang","doi":"10.1186/s12981-026-00911-3","DOIUrl":"10.1186/s12981-026-00911-3","url":null,"abstract":"<p><strong>Background: </strong>Despite effective antiretroviral therapy (ART), a subset of people living with HIV(PLWH)experiences low-level viremia(LLV), yet its impact on subsequent virologic failure (VF) and immunologic failure (IF) remains unclear. This study aims to elucidate the effect of LLV on the risk of VF and IF.</p><p><strong>Methods: </strong>This retrospective cohort study included PLWH aged ≥ 18 years who initiated ART in Qinzhou City, Guangxi, China, from 2005 to 2023. Participants were categorized into mutually exclusive viral load categories: undetectable viral load (≤ 50 copies/mL) and LLV (51-999 copies/mL). Time-updated Cox proportional hazards models were used to evaluate the association between LLV and the risk of VF and IF.</p><p><strong>Results: </strong>A total of 4,274 participants were followed for 12,288.35 person-years, with a median follow-up of 3.03 years. Among these participants, 11.16% experienced at least one LLV event. Compared to those with an undetectable viral load, individuals with LLV had a significantly higher risk of VF (adjusted hazard ratio [aHR] = 5.23, 95% CI: 3.48-7.85), with intermittent low-level viremia (ILLV) showing the strongest association (aHR = 7.34, 95% CI: 4.92-10.94). Conversely, LLV was associated with a lower risk of IF compared with an undetectable viral load (aHR = 0.59, 95% CI: 0.37-0.92), a finding consistent with the reduced risk observed in the ILLV subgroup (aHR = 0.56, 95% CI: 0.33-0.96).</p><p><strong>Conclusions: </strong>Patients with LLV had an increased risk of subsequent VF, emphasizing the need for close monitoring of viral load and potential treatment adjustments to optimize long-term ART outcomes.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13625323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"People with HIV on antiretroviral therapy demonstrate robust humoral response to influenza vaccination.","authors":"Preeti Moar, Pauline A Ocaya, Christoffer Granvik, Julia Wigren Byström, Koushikul Islam, Niklas Arnberg, Therese Thunberg, Mattias N E Forsell","doi":"10.1186/s12981-026-00917-x","DOIUrl":"10.1186/s12981-026-00917-x","url":null,"abstract":"<p><p>We evaluated the magnitude and function of antibody responses to seasonal influenza vaccination in individuals with HIV receiving ART compared with individuals without HIV. In a prospective cohort of 78 adults, influenza strain-specific IgG levels were measured up to one-year post-vaccination. Linear mixed-effects models assessed longitudinal trends. IgG levels peaked at two weeks and declined gradually in both groups. HIV status did not significantly influence antibody magnitude or neutralizing activity, and H1N1 antibody levels correlated with neutralization titers. These findings demonstrate robust, durable, and functional humoral response in well-controlled HIV, supporting the effectiveness of annual influenza vaccination in this population.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13340008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes after the implementation of a patient-centered care program applied to newly admitted people with HIV in Mexico City: a retrospective cohort study.","authors":"Roxana Claudia Iquize Condori, Jessica Mejía-Castrejón, Yanink Caro-Vega, Héctor Orlando Rivera Villegas, Ana Paula Villalobos-Hernández, Sharon Daniela Ortiz Valdespino, Tavata Bejarano Colina, Álvaro López Iñiguez, Brenda Eloisa Crabtree-Ramírez","doi":"10.1186/s12981-026-00916-y","DOIUrl":"10.1186/s12981-026-00916-y","url":null,"abstract":"<p><strong>Background: </strong>Although antiretroviral therapy (ART) has improved life expectancy in people living with HIV (PWH), sustained HIV care remains a critical challenge. The Newly Admitted Patients Program (NAPP), a local Patient-Centered Care (PCC) intervention, was implemented for patients admitted via the HIV clinic. We aimed to evaluate clinical outcomes (loss to follow-up (LTFU), hospitalization, treatment discontinuation (TD), virologic failure, and mortality) among participants in NAPP versus non-participants (No-NAPP).</p><p><strong>Materials and methods: </strong>We conducted a retrospective cohort study at a single tertiary-care center, including PWH from January 2015 to December 2023. Participants were followed from enrollment in the HIV clinic to their last visit. Clinical, demographic, and laboratory variables were analyzed, and adjusted logistic regression was used to identify factors associated with clinical outcomes.</p><p><strong>Results: </strong>We included 758 participants: 387 (51.1%) in the NAPP group and 371 (48.9%) in No-NAPP. NAPP participants were younger (median age 32 vs. 37 years, p < 0.01), more often MSM (78% vs. 70.1%, p = 0.04), and education levels differed (p = 0.014), though university/postgraduate attainment was similar between groups (53.7% vs. 55.8%). At follow-up, the NAPP group had lower rates of LTFU (10.9% vs. 27.8%, p < 0.01), hospitalization (21.9% vs. 32.6% p < 0.01), and mortality (3.4% vs. 8.9%, p < 0.01). NAPP participation was independently associated with reduced risk of LTFU (OR = 0.32, 95% CI = 0.22-0.49), hospitalization (OR = 0.61, 95% CI 0.44-0.86), and death (OR = 0.42, 95% CI = 0.21-0.85).</p><p><strong>Conclusions: </strong>Despite similar virological and immunological characteristics at baseline, those who participated in NAPP intervention experienced fewer unfavorable clinical outcomes, highlighting the importance of PCC programs in improving health outcomes for PWH.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From vertical silos to integrated care: administrative agility and normalization of HIV services in Tamil Nadu, India.","authors":"Essa M Rafique, Abdul M Ruknudin, Sadiq Bukhari, Mohammad A Akbarsha","doi":"10.1186/s12981-026-00897-y","DOIUrl":"10.1186/s12981-026-00897-y","url":null,"abstract":"<p><strong>Background: </strong>While India's HIV epidemic discloses substantial inter-state heterogeneity, Tamil Nadu (TN) achieved one of the country's earliest and most sustained reversals in transmission. Once a high-burden state, TN successfully decoupled its trajectory from other high-prevalence southern regions. This review examines the 'Tamil Nadu Model,' benchmarking its performance against West Bengal and global high-performers to identify specific drivers of success while comparing it with Karnataka, Maharashtra, and undivided Andhra Pradesh.</p><p><strong>Methods: </strong>We synthesized longitudinal data (2000-2024) from HIV Sentinel Surveillance (HSS), IBBS, NACO Spectrum estimates, and NFHS reports. Using a Strategic Blueprints (SB) framework, we analyzed 13 key epidemiological and health-system indicators, including TB-HIV collaborative care. We compared Tamil Nadu's performance with Karnataka, Maharashtra, undivided Andhra Pradesh, and West Bengal, as well as international benchmarks including Thailand, New South Wales, and KwaZulu-Natal.</p><p><strong>Results: </strong>Tamil Nadu recorded a 94% reduction in annual new infections, with adult prevalence falling from 1.15% (2000) to 0.16% (2024). TN became the first major Indian state to achieve the WHO threshold for eliminating vertical transmission (< 5%). Comparative analysis demonstrates that TN's \"Administrative Agility\" facilitated faster declines than low-intensity states like West Bengal. Furthermore, integrating TB-HIV services via the Ni-kshay platform and \"Four-S\" screening protocols achieved near-universal status awareness among TB patients, accelerating progress toward UNAIDS 95-95-95 targets.</p><p><strong>Conclusion: </strong>Tamil Nadu's trajectory proves that administrative agility and institutional normalization are more effective than vertically siloed interventions. Its ability to outperform regional peers and global benchmarks underscores the robustness of its Strategic Blueprints. As programs transition toward 2030, integrating HIV care with non-communicable disease and TB management offers a scalable road-map for sustained control. Ultimately, shifting from state-level data to global policy lessons positions the \"Tamil Nadu Model\" as a transferable framework for ending AIDS in resource-limited settings worldwide.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with prevalent hypertension among adults living with HIV receiving antiretroviral therapy in Yaounde, Cameroon: a cross-sectional study.","authors":"Francis Duhamel Nang Nang, Liliane Mfeukeu Kuate, Paul Junior Chebo, Anastase Dzudie, Luc Baudoin Fankoua Tchaptcha, Andre Pascal Kengne, Jean Pierre Junior Tchitetchoun, Francois Anicet Onana Akoa, Rita Marie Ifoue, Lawson Ngwagwe Mbolueh, Charles Kouanfack, Simeon Pierre Choukem","doi":"10.1186/s12981-026-00905-1","DOIUrl":"10.1186/s12981-026-00905-1","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a frequent comorbidity among people living with HIV (PLHIV) in sub-Saharan Africa, but analytical data from routine HIV clinics in Cameroon remain limited. This study assessed factors associated with prevalent hypertension among adults receiving antiretroviral therapy (ART) at an urban HIV clinic in Yaounde, Cameroon.</p><p><strong>Methods: </strong>We conducted a cross-sectional study at the Day Hospital of Yaounde Central Hospital between January and March 2024. The analytical dataset included 460 adults living with HIV receiving ART. Prevalent hypertension was coded as a binary outcome. Robust Poisson regression was used to estimate prevalence ratios (PRs) and adjusted prevalence ratios (aPRs) because hypertension was common. Sensitivity models were fitted to clarify the interpretation of cumulative ART duration in relation to current age.</p><p><strong>Results: </strong>Among 460 participants, 199 (43.3%) had prevalent hypertension. The mean age was 50.5 ± 10.9 years, and 338 (73.5%) participants were women. In bivariable analysis, older age (PR per 1-year increase 1.02, 95% CI 1.01-1.03; p < 0.001), longer ART duration (PR per 1-year increase 1.03, 95% CI 1.01-1.05; p < 0.001), family history of hypertension (PR 2.98, 95% CI 2.40-3.71; p < 0.001), HIV stage II at ART initiation (PR 1.29, 95% CI 1.03-1.60; p = 0.024), and obesity (PR 1.43, 95% CI 1.10-1.87; p = 0.007) were associated with hypertension. In the final multivariable model, older age (aPR 1.02, 95% CI 1.01-1.03; p = 0.002), family history of hypertension (aPR 2.83, 95% CI 2.25-3.57; p < 0.001), and obesity (aPR 1.29, 95% CI 1.01-1.65; p = 0.045) remained independently associated with prevalent hypertension, whereas cumulative ART duration was not independently associated after adjustment (aPR 1.00, 95% CI 0.99-1.02; p = 0.619). Restricted cubic spline analysis did not show evidence of an overall association or non-linearity for ART duration.</p><p><strong>Conclusions: </strong>In this urban HIV clinic, hypertension was frequent and was associated mainly with age, family history of hypertension, and obesity in the adjusted model. Cumulative ART duration was associated with hypertension in crude or minimally adjusted models but not after adjustment for age and cardiometabolic factors. These findings support integrating routine blood-pressure screening, weight management, lifestyle counselling, and standardized hypertension care into HIV services.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13551911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived social support and its impact on alcohol treatment outcomes: a qualitative study among women with HIV enrolled in a clinical alcohol pharmacotherapy trial.","authors":"Nanyangwe Siuluta, Abigail Gracy, Sashaun Ranger, Christina E Parisi, Rebecca J Fisk-Hoffman, Isaac Payton, Robert L Cook, Shantrel S Canidate","doi":"10.1186/s12981-026-00915-z","DOIUrl":"10.1186/s12981-026-00915-z","url":null,"abstract":"<p><strong>Background: </strong>Motivation to engage in treatment and maintain adherence is essential for people with unhealthy alcohol use. Social support may increase motivation to engage in treatment. Still, there is limited knowledge regarding social support providers and types of social support that facilitate or hinder alcohol treatment participation among women with HIV (WWH). This study explores social support among WWH in Florida: types, sources, and perceived impact on drinking outcomes.</p><p><strong>Methods: </strong>Semi-structured interviews were conducted with 20 WWH (mean age 49, 85% Black) with a history of unhealthy drinking enrolled in an alcohol pharmacotherapy trial. Participants discussed their sources, types, and the importance of social support in trial participation. Transcripts were thematically analyzed using NVivo 12.0.</p><p><strong>Results: </strong>The most mentioned source of social support was social networks, including family and friends. Abstinent family members provided more support by discouraging drinking and motivating recovery. The most frequently mentioned types of social support for alcohol treatment were emotional, including non-judgmental listening, trustworthiness, and care, as well as informational, such as teaching WWH about new topics and engaging them in conversations. Women also emphasized the importance of encouragement and open discussions in alcohol treatment.</p><p><strong>Conclusion: </strong>WWH highlighted that social support from their social networks benefited their alcohol treatment through engagement and positive social interactions. Encouraging support is essential. Thus, social support reinforces adherence to both alcohol use and HIV treatment, thereby improving outcomes across the HIV care continuum in underserved communities.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13584268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}